isabelobrien, Author at European Medical Journal

Gold coins on blue background

VPAG 2026 rate set at 14.5%, post US tariff deal

Industry leaders cautiously welcome the step but warn that more reform is needed if the UK is to regain its competitive edge.

Dr Michael Zaiac

Daiichi Sankyo's Dr Michael Zaiac on moving beyond 'sick care'

Daiichi Sankyo’s Dr Michael Zaiac discusses how AI, biomarkers and targeted therapies are shaping oncology.

Handshake on globe backdrop

US tariff deal: what it means for UK pharma

Last week, the UK and US signed a zero tariff pharmaceuticals deal, but what will the deal deliver in the long term, and is all as it seems?

Month in pharma news, explained

Month in pharma news, explained – November 2025

In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on November 2025.

Clinical trial participant

ABPI: UK falling behind on clinical trial recruitment

According to the body, patient participation in industry-sponsored trials has fallen by 25% between 2022/23 and 2024/25.

Carol Pitcher-Towner

Carol Pitcher-Towner on the gender health divide

This week, Isabel sits down with Carol Pitcher-Towner, Alnylam, to unpack the gender inequities that continue to shape modern healthcare.

Vaccine

Europe’s vaccine pipeline has 91 candidates in R&D

Crucially, 41% of these candidates target pathogens for which no vaccines or prophylactic monoclonal antibodies are currently registered.

Cartoon brain on green background

Epileptic seizure detection device to launch in Europe

A wearable device that can alert patients and caregivers minutes before a seizure occurs is set to launch across Europe.

Spanish buildings on blue background

Pharma in Spain

Spain’s pharma sector is a hub for clinical trials, exports and digital innovation, but access and value-based reforms remain key.

Doctor and patient discussing depression

AbbVie and BioMed X to study science of lost joy

The two companies have launched a collaborative research initiative to investigate anhedonia in depression, hoping to solve huge unmet needs.